These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 29451049)
1. The increase in bone mineral density by bisphosphonate with active vitamin D analog is associated with the serum calcium level within the reference interval in postmenopausal osteoporosis. Kinoshita M; Ishijima M; Kaneko H; Liu L; Nagao M; Sadatsuki R; Hada S; Arita H; Aoki T; Yamanaka M; Nojiri H; Sakamoto Y; Tokita A; Kaneko K Mod Rheumatol; 2019 Jan; 29(1):157-164. PubMed ID: 29451049 [TBL] [Abstract][Full Text] [Related]
2. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis. Deane A; Constancio L; Fogelman I; Hampson G BMC Musculoskelet Disord; 2007 Jan; 8():3. PubMed ID: 17214897 [TBL] [Abstract][Full Text] [Related]
3. Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment. Iba K; Sonoda T; Takada J; Dohke T; Yamashita T J Bone Miner Metab; 2017 Mar; 35(2):171-176. PubMed ID: 26832388 [TBL] [Abstract][Full Text] [Related]
4. Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women. Ishijima M; Sakamoto Y; Yamanaka M; Tokita A; Kitahara K; Kaneko H; Kurosawa H Calcif Tissue Int; 2009 Nov; 85(5):398-404. PubMed ID: 19795092 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss. McClung MR; Bolognese MA; Sedarati F; Recker RR; Miller PD Bone; 2009 Mar; 44(3):418-22. PubMed ID: 18950736 [TBL] [Abstract][Full Text] [Related]
6. Clinical Research of the Application of Bone Turnover Markers in Monitoring the Short-Term Therapeutic Efficacy of Vitamin D in Postmenopausal Osteoporotic women in Harbin, China. Zhang Y; Wang Y J Nutr Health Aging; 2020; 24(5):485-493. PubMed ID: 32346686 [TBL] [Abstract][Full Text] [Related]
7. Relationship between increased endogenous parathormone levels and bone density in postmenopausal women treated with bisphosphonates. Coin A; Veronese N; Bolzetta F; De Rui M; Manzato E; Sergi G Panminerva Med; 2012 Dec; 54(4):277-82. PubMed ID: 23123579 [TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid increases bone mineral density and improves health-related quality of life over two years of treatment in Chinese women with postmenopausal osteoporosis. Huang S; Lin H; Zhu X; Chen X; Fan L; Liu C Endokrynol Pol; 2014; 65(2):96-104. PubMed ID: 24802732 [TBL] [Abstract][Full Text] [Related]
10. Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status. Mok J; Brown C; Moore AEB; Min SS; Hampson G Endocr Res; 2018 Aug; 43(3):195-202. PubMed ID: 29652557 [TBL] [Abstract][Full Text] [Related]
11. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday. Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963 [TBL] [Abstract][Full Text] [Related]
12. Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease. Stokkers PC; Deley M; Van Der Spek M; Verberne HJ; Van Deventer SJ; Hommes DW Scand J Gastroenterol; 2006 Feb; 41(2):200-4. PubMed ID: 16484125 [TBL] [Abstract][Full Text] [Related]
13. Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis. Mandema JW; Zheng J; Libanati C; Perez Ruixo JJ J Clin Endocrinol Metab; 2014 Oct; 99(10):3746-55. PubMed ID: 24915115 [TBL] [Abstract][Full Text] [Related]
14. Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal women. Augoulea A; Tsakonas E; Triantafyllopoulos I; Rizos D; Armeni E; Tsoltos N; Tournis S; Deligeoroglou E; Antoniou A; Lambrinoudaki I J Musculoskelet Neuronal Interact; 2017 Mar; 17(1):444-449. PubMed ID: 28250248 [TBL] [Abstract][Full Text] [Related]
15. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments. Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192 [TBL] [Abstract][Full Text] [Related]
16. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment. Sebba AI Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784 [TBL] [Abstract][Full Text] [Related]
17. Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis. Nuti R; Bianchi G; Brandi ML; Caudarella R; D'Erasmo E; Fiore C; Isaia GC; Luisetto G; Muratore M; Oriente P; Ortolani S Rheumatol Int; 2006 Mar; 26(5):445-53. PubMed ID: 16283320 [TBL] [Abstract][Full Text] [Related]
18. 25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis. Peris P; Martínez-Ferrer A; Monegal A; Martínez de Osaba MJ; Muxi A; Guañabens N Bone; 2012 Jul; 51(1):54-8. PubMed ID: 22487299 [TBL] [Abstract][Full Text] [Related]
19. A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates. Cosman F; Gilchrist N; McClung M; Foldes J; de Villiers T; Santora A; Leung A; Samanta S; Heyden N; McGinnis JP; Rosenberg E; Denker AE Osteoporos Int; 2016 Jan; 27(1):377-86. PubMed ID: 26556736 [TBL] [Abstract][Full Text] [Related]
20. Potential association with early changes in serum calcium level after starting or switching to denosumab combined with eldecalcitol. Asano T; Shimizu T; Takahashi D; Ota M; Sato D; Hamano H; Hiratsuka S; Takahata M; Iwasaki N J Bone Miner Metab; 2019 Mar; 37(2):351-357. PubMed ID: 29721807 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]